Exclusive Summary

• Original patents have expired, indicating a mature generic market with extensive sales opportunities.
• The global burden of cardiovascular disease is immense, ensuring a broad market demand for this fixed-dose combination.
• The product's clear clinical value, inclusion in the WHO Essential Medicines List, and guideline recommendations solidify its treatment status.
• China's bioequivalence approval (一致性评价) confirms quality equivalence to the innovator, offering a strong position for international partnerships based on cost-effectiveness.
• As a fixed-dose combination, it simplifies treatment regimens, potentially enhancing patient compliance and expanding market reach.

Asset Materials

Contact Us for Full Materials